The CReST Trial is OPEN at 48 Centres!!
With over 100 patients, CReST is now the biggest colorectal stenitng trial in Europe!
For our latest news, updated recruitment figures and information about the Dutch Stent-In II trial please see the CReST newsletter - September 2010
For up-to-date recruitment figures, please check the UKCRN portfolio database: http://public.ukcrn.org.uk/search/
-
The first patient was randomised at Manchester Royal Infirmary by the Chief Investigator for the trial, Mr Jim Hill, on 23 April 2009.
-
There are now 48 sites open to recruitment. To see the list of participating centres please click here.
For further information, or to express interest in participating in the CReST study, please contact the CReST study office:
E-mail : CReST@contacts.bham.ac.uk
Tel: 0121 415 9105
Randomisation
For Randomisation go to www.trials.bham.ac.uk/CReST or call 0800 953 0274
If you do not have log in details please contact the CReST office who will be able to set these up for you.
CReST - The role of endoluminal stenting in the acute management of obstructing colorectal cancer.
The primary objectives of the CReST RCT are to establish if endoluminal stenting for obstructing colonic cancers can result in:
-
Reduced perioperative morbidity and reduced length of hospital stay.
-
Reduced stoma formation,
-
A measurable improvement in quality of life.